SS
Chief Scientific Officer
Get the full picture
Sign in to uncover key details.
EydisBio
Business Services · North Carolina, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
201 W Main St Ste 317, Durham, North Car...Website
www.eydisbio.comRevenue
<$5 MillionIndustry
About EydisBio
EydisBio is a biotech startup based in Durham, NC, specializing in the development of highly selective small molecule kinase inhibitors targeting autoimmune and inflammatory diseases. Their primary focus is on creating a novel TAK1 inhibitor that is orally bioavailable, aimed at providing safer and more effective treatments for conditions such as rheumatoid arthritis, chronic pain, and systemic sclerosis. The company addresses significant unmet medical needs, particularly for patients seeking alternatives to existing anti-TNF biologics. EydisBio's innovative approach leverages a unique discovery platform to develop a pipeline of small molecules that target disease-driving proteins.Explore more
EydisBio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to EydisBio
Compare insights from companies similar to EydisBio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
EydisBio Tech Stack
A closer look at the technologies used by EydisBio
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding EydisBio
Sign Up For FreeTo access detailed company insights
EydisBio is a biotech startup based in Durham, NC, specializing in the development of highly selective small molecule kinase inhibitors targeting autoimmune and inflammatory diseases. Their primary focus is on creating a novel TAK1 inhibitor that is orally bioavailable, aimed at providing safer and more effective treatments for conditions such as r... Read More
